Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands

BACKGROUND: The phase 3 clinical trial KEYNOTE-426 suggested a higher efficacy regarding overall survival (OS) and progression-free survival (PFS) of pembrolizumab+axitinib compared to sunitinib as a first-line treatment for patients with advanced renal cell carcinoma. In this analysis, the potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Xander, Nicolas S. H., Fiets, W. Edward, Uyl-de Groot, Carin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336227/
https://www.ncbi.nlm.nih.gov/pubmed/37448519
http://dx.doi.org/10.3389/fonc.2023.1205700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336227/
https://www.ncbi.nlm.nih.gov/pubmed/37448519
http://dx.doi.org/10.3389/fonc.2023.1205700

Ejemplares similares